The global pharmaceutical industry experienced a 23% decline in the number of environmental sustainability-related patent applications in Q1 2023 compared with the previous quarter. The total number of environmental sustainability-related grants dropped by 24% in Q1 2023, according to GlobalData’s Patent Analytics. With an increasing focus on ESG, Pharmaceutical companies are under pressure to incorporate sustainability with suppliers playing a crucial role in the process. GlobalData’s ESG (Environmental, Social and Governance) Survey on Pharmaceutical Manufacturing – Towards a Sustainable Supply Chain report includes the ESG measures and response, and ESG Ratings of Pharmaceutical Companies as assessed by leading ESG rating agencies. Buy the report here.
Notably, the number of environmental sustainability-related patent applications in the pharmaceutical industry was 1,948 in Q1 2023, versus 2,528 in the prior quarter.
The top one companies accounted for 0.05% of patenting activity
Analysis of patenting activity by companies shows that Zhejiang Hisun Pharmaceutical filed the most environmental sustainability patents within the pharmaceutical industry in Q1 2023. The company filed 1 environmental sustainability-related patent in the quarter. in Q1 2023.
Patenting activity was driven by China with 0.05% share of total patent filings
The largest share of environmental sustainability related patent filings in the pharmaceutical industry in Q1 2023 was in China with 0.05%, followed by . The share represented by China was 0.03% lower than the 0.08% share it accounted for in Q4 2022.
To further understand GlobalData's analysis on ESG (Environmental, Social, and Governance) in Pharma – Thematic Research buy the report here.